Answers are grounded in this paper and cite their sources.
Dr. Rado is Assistant Professor, Psychiatric Clinical Research Center, Rush University Medical Center, 2150 West Harrison, Office 262, Chicago, IL 60612; E-mail: [email protected]. Dr. Rado has disclosed that he was the recipient of grant/research support from Solvay, Bristol-Myers Squibb, Sanofi-Adventis, and Johnson & Johnson; is the recipient of grant/research support from Otsuka, Neuronetics, Inc., Eli Lilly, and Pfizer; and is a consultant to Neuronetics, Inc. The author also has disclosed that the use of omega-3 fatty acids for treatment of depression as discussed in this article has not been approved by the U.S. Food and Drug Administration. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. This continuing education activity is intended for psychiatrists and other health care professionals with an interest in psychotropic drug therapy.
No takes yet. Share an insight, caveat, or question.
Jeffrey T. Rado (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: